CHAPTER 7 Methods of Tertiary Prevention 215 Keogh KM, Smith SM, White P, et al: Psychological family 25. Ong KL, Cheung BMY, Man YB, et al: Prevalence, awareness, 17:105-11 adults, 1999-2004. Hypertension 4 -75,2007 4. Goulding L, Furze G, Birks Y: Randomized controlled trials of 26. Svetkey LP, Sacks FM, Obarzanek E, et al; The DASH diet, with coronary heart disease: svetave illness beliefs in people sodium intake, and blood pressure trial( DASH-sodium): rationale and design. J Am Diet Assoc 99(suppl 8): 96-104, 1999 66:946-961,2010 27. Yusuf S, Sleight P, Pogue J, et al: Effects of 5. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coro converting enzyme inhibitor, ramipril, on cardiovascular events nary heart disease in subjects with type 2 diabetes and in non high-risk patients. N Engl J Med 342: 145-153, 2000 it prior myocar 8. Bangalore S, Sawhney S, Messerli FH: Relation of beta-blocker- N Engl Med339:229234,1998 induced heart rate lowering 6. Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al: Is sion. J Am Coll Cardio! 52: 1482-1489, 2008 a coronary risk equivalent? Systematic review and meta- 29. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hyper alysis, Diabet Med 26: 142-148, 2009 nsion: is it a wise choice? Lancet 364(9446): 1684-1689, 2004 7 Breslow L: Risk factor intervention for health maintenance. 30. US Centers for Disease Control and prevention: chror lence200:908912,1978 disease prevention and health prevention: diabetes successes 8. Dawber TR, Meadors GE, Moore FE Jr: Epidemiologie d opportunities for population-based prevention and control pproaches to heart disease: the Framingham Study. Am J at a glai Public Health 41: 279-286, 1951 9. Healy GN, Matthews CE, Dunstan Dw, et al: Sedentary time 31. Diabetes Control and Complications Trial. DCCT Research and cardio-metabolic biomarkers in U.S. adults: NhaneS Group. N Engl/ Med 329: 683-689, 1993 2003-06. Eur heart32:590597,2011 32. Santiago JV: Lessons from the Diabetes Control and Complica 10. Lissner L, Odell PM, D' Agostino RB, et al: Variability of body tions Trial. Diabetes 42: 1549-1554, 1993 reight and health outcomes in the Framingham population 33, Stratton IM, Adler AL, Neil HA, et al: Association of glycaemia N Engl med32418391844,1991 with macrovascular and microvascular complications of typ 11. Wing RR, Jeffery RW, Hellerstedt WL: A prospective study of diabetes: prospective observational study. BM/321: 405-412 effects of weight cycling on cardiovascular risk factors. Arch stern Med155:1416-1422,1995 34.H W, et al: Is glycem 12. Gotto AM, Pownall H]: Manual of lipid disorders, ed 3, Balti in U.S. adults? diabetes Care 31: 81-86, 2007 more, 2002, williams& wilkins. 35. Bennett WL, Maruthur NM, Singh S, et al: Comparative effec- 3. Sumithran P, Prendergast LA, Delbrid et tiveness and safety of medications for type 2 diabetes: an ersistence of hormonal adaptations to weight loss. N EnglJ pdate inch Med365:1597-1604,201l. Intern med154:602-613,2011 14. Cereda E, Malavazos AE, Caccialanza R, et al: Weight cycling is 36. Piepoli MF, Corra U, Benzer W, et al: Secondary prevention associated with body weight excess and abdominal fat accum through cardiac rehabilitation: from knowledge to implemen- lation: a cross-sectional study. Clin Nutr 30: 718-723, 2011 tation. Cardiac Rehabi of E Association 15. Taing KY, Ardern CI, Kuk JL: Effect of the timing of weight for Cardiovascular Prevention and Rehabilitation. Eur J Car- cycling during adulthood on mortality risk in overweight diovasc Prey rehabil 17: 1-17. 2010 menopausal women. Obesity( Silver S 37. Mead H, Andres e, Ramos C, et al: Barriers to effecti 413,2012 rdiac patients: the patients'ex ive self- 16. Strohacker K, McFarlin BK: Influence of obesity, physical inac Patient Educ Counsel 79: 69-76, 2010 tivity, and weight cycling on chronic inflammation. Front biosci ez F, Naunheim K, et al: A ra comparing olume-reduction su 7. Field AE, Malspeis S, willett WC: Weight cycling and mortality emphysema. N Engl J Med among middle-aged or older women. Arch Intern Med 169: 881- 2003 39. Puhan MA, Gimeno-Santos E tzm, et al: Pulmona 18. National Cholesterol Education Program: Executive summary rehabilitation following exace of the third report of the NCEP Expert Panel on Detection, Syst Rev(10): CD005305 Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001 40. Spence RR, Heesch KC, WJ: Exercise and cancer 19.http://www.nhlbi.nihgov/guidelines/cvd_adult/background Cancer Treat rey 36: 185 20. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: primary 41. LaDou J: Occupational and environmental medicine, ed 3, Stam revention trial with gemfibrozil in middle-aged men with ord, Conn, 2004, Appleton Lange lipidemia. N Engl Med 317: 1237-1245, 1987. 21. Arntzenius AC, Kromhout D, Barth JD, et al: Diet, lipoproteins, Intervention Trial. N Engl)Med, atherosclerosis: the Leiden Select Readings and the progression of corona 5-811,1985 22. Smulders YV, Blom HJ: The homocysteine controversy. J Inh Diabetes Control and Complications Trial, DCCT Research Group Metab Dis 34: 93-99. 2011 N Engl J Med329:683689,1993 L, et al: Effect of homocysteine int Franklin D]: Cancer rehabilitation: challenges, approaches, and new entions on the risk of cardiocerebrovascular events: a meta directions. Phys Med rehabil Clin North Am 18: 899-924, 2007. nalysis of randomised controlled trials. Int J Clin Pract Gordon DL, Katz DL: Stealth health: how to sneak age-defying, 64:208-215,2010. disease-fighting habits into your life without really trying. Pleas 24. National Institutes of Health, National Heart, Lung, and Blood antville, NY, Readers'Digest 2005 [Information for patients. J Institute: The Seventh Report of the Joint National Committee Gotto AM, Pownall H]: Manual of lipid disorders, ed 3, Baltimore on Prevention, Detection, Evaluation, and Treatment of High 2002, Williams wilkins BloodPressure2003;http://www.nhlbi.nih.gov/guideline Hypertensiontreatmentguidelineswww.nhlbi.nih.gow/guidelines/